The alternative complement pathway plays a key role in the pathogenesis of IgA nephropathy. Iptacopan specifically binds to factor B and inhibits the alternative pathway. In this phase 3 ...

Changes in complement pathway biomarkers were consistent with selective alternative pathway inhibition, marked by median changes from baseline in the following: Bb plasma: -21.1% with iptacopan vs ...

Both result from a problem with a specific part of the immune system called the alternative complement pathway. Both types of C3 glomerulopathy can cause significant kidney disease and have a ...

“The analyses from this study add to the body of evidence that show Factor D inhibition can correct dysregulation of the alternative pathway and ... for multiple complement-mediated diseases.

The three complement activation pathways include the classical pathway, the alternative pathway, and the lectin pathway. Individuals with long COVID at six months showed increased expression of ...

Interim data from Phase 1/2a study demonstrate near complete inhibition in hemolytic activity and functional activity of alternative complement pathway Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) ...

In a recent study on the medRxiv* preprint server, researchers identified an interleukin 6 (IL-6) dependent alternative pathway as a therapeutic strategy against coronavirus disease 2019 (COVID-19).

TSP-1 reduced C3 and C5 cleavage and formation of the membrane attack complex, attenuating complement-mediated injury in AAV models. Complement activation is a relevant driver in the ...

PASADENA, Calif., April 24, 2024--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial (NCT06209177 ...

Iptacopan is an innovative, first-in-class oral small molecule that reversibly inhibits factor B—a crucial serine protease in the alternative pathway of the complement system. By targeting this ...

“ARO-CFB also demonstrated dramatic reductions in measures of alternative complement pathway activation, with mean reductions at or approaching 100% in AH50 and Wieslab AP at multiple dose level ...

SAN DIEGO -- There was a clinically meaningful reduction in proteinuria with iptacopan (Fabhalta), and a confirmed clinical benefit of alternative pathway inhibition, in a rare kidney disorder ...